Comparative Pharmacology
Head-to-head clinical analysis: AUREOMYCIN versus MECLAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUREOMYCIN versus MECLAN.
AUREOMYCIN vs MECLAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
Meclizine is an antihistamine with central anticholinergic properties. It blocks histamine H1 receptors and exerts antiemetic effects via inhibition of the vestibular system and chemoreceptor trigger zone.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
250 mg orally three times daily for 7-14 days; for sinusitis: 500 mg three times daily.
None Documented
None Documented
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
Terminal elimination half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Renal excretion of unchanged drug and metabolites: ~70%; fecal/biliary: ~30%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic